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Recent studies identiﬁed MYH9 as a major susceptibility gene for common forms of non-diabetic end-stage
kidney disease (ESKD). A set of African ancestry DNA sequence variants comprising the E-1 haplotype,
was signiﬁcantly associated with ESKD. In order to determine whether African ancestry variants are also
associated with disease susceptibility in admixed populations with differing genomic backgrounds, we gen-
otyped a total of 1425 African and Hispanic American subjects comprising dialysis patients with diabetic and
non-diabetic ESKD and controls, using 42 single nucleotide polymorphisms (SNPs) within the MYH9 gene
and 40 genome-wide and 38 chromosome 22 ancestry informative markers. Following ancestry correction,
logistic regression demonstrated that three of the E-1 SNPs are also associated with non-diabetic ESKD
in the new sample sets of both African and Hispanic Americans, with a stronger association in Hispanic
Americans. We also identiﬁed MYH9 SNPs that are even more powerfully associated with the disease
phenotype than the E-1 SNPs. These newly associated SNPs, could be divided into those comprising a
haplotype termed S-1 whose association was signiﬁcant under a recessive or additive inheritance mode
(rs5750248, OR 4.21, P < 0.01, Hispanic Americans, recessive), and those comprising a haplotype termed
F-1 whose association was signiﬁcant under a dominant or additive inheritance mode (rs11912763, OR
4.59, P < 0.01, Hispanic Americans, dominant). These ﬁndings strengthen the contention that a sequence
variant of MYH9, common in populations with varying degrees of African ancestry admixture, and
in strong linkage disequilibrium with the associated SNPs and haplotypes reported herein, strongly
predisposes to non-diabetic ESKD.
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Epidemiologic data from the USA consistently demonstrate a
signiﬁcantly greater risk for end-stage kidney disease (ESKD)
among African Americans (incidence rate of 1010 per million
population) compared with European Americans (279 per
million population) (1). This discrepancy is evident for
many major etiologies of ESKD, including sporadic cases of
focal segmental glomerulosclerosis (FSGS), non-diabetic
ESKD associated with hypertension and HIV-1 associated
FSGS (African American risk ratio compared with European
Americans of 4-, 5.3- and 18-fold, respectively) (1–3). Impor-
tantly, these discrepancies were shown to persist even after
socioeconomic differences were considered, leading many to
hypothesize that a population-based genetic predisposition,
likely related to African ancestry, is responsible for the
observed elevated risk for ESKD among African Americans.
A similar discrepancy in ESKD incidence rates of lesser mag-
nitude is also well documented for Hispanic Americans (inci-
dence rate of 520 per million population) (1).
Concordant with this epidemiological data and the suggested
hypothesis, two recently published studies demonstrated a
strong association of genetic variants in the MYH9 gene,
located on chromosome 22, encoding the molecular motor
protein non-muscle myosin heavy chain IIA, with ESKD in
African Americans (4,5). These two studies used mapping by
admixture linkage disequilibrium (LD) in African Americans
to identify the MYH9 gene, as a single major disease suscepti-
bility locus for ESKD. The association in these studies was
strongest with a set of four single nucleotide polymorphisms
(SNPs) which deﬁned a risk haplotype, termed the E-1 haplo-
type (5). In particular, the risk conferred by African ancestry
at this genetic locus was only evident for non-diabetic ESKD
etiologies, and was strongest for FSGS, human immunodeﬁ-
ciencyvirus-associatednephropathy(HIVAN)andhypertension
associated ESKD. A subsequent study conﬁrmed the strong
association of the MYH9 gene with hypertension associated
ESKD in African Americans (6). More recently, an association
with ESKD among diabetic African Americans was attributed
to the undiagnosed subset of non-diabetic glomerulopathy,
well-documented among patients with coincident diabetes and
ESKD (7).
The epidemiological association between individuals of
African ancestry and higher incidence of ESKD due to idio-
pathic FSGS or HIVAN has also been reported outside of
the USA (3,8–10) and in the case of HIVAN was further
suggested to be speciﬁcally related to West African Ancestry
(11) but has not been studied at the genetic level in these popu-
lations. Recently, Pattaro et al. (12) replicated the genetic
association of serum creatinine levels with the MYH9 gene
polymorphisms in European non-diabetic individuals, indicat-
ing that this gene may inﬂuence kidney function in non-
Africans as well. Interestingly, two of the SNPs reported by
Kopp et al. (5) to comprise part of the E-1 risk haplotype
observed among non-diabetic African Americans, were also
tested by Pattaro et al. (12), but were not associated with elev-
ated creatinine levels among non-diabetic ESKD Europeans.
Another recent study showed an association of the E-1
haplotype with albuminuria levels in hypertensive African
Americans (13). Cumulatively, these lines of evidence
suggest a marked effect of MYH9 polymorphisms on kidney
function or disease susceptibility. However, the question as
to whether the same protective or risk polymorphisms simi-
larly affect populations of various distinct geographic origins
remains open. In this regard, the potential to study MYH9
risk polymorphisms reported among African Americans in
an additional population known to have both African ancestry
and a higher incidence of ESKD is of particular interest, and
might lend further insight into our understanding of the role
of genetic patterns in ESKD vulnerability, particularly with
respect to the role of African ancestry risk variants at the
MYH9 locus.
To this end, the population of Hispanic Americans presents
an important opportunity. It is well established that the various
Hispanic American communities have varying degrees of
admixture of Native American, African and European ances-
tries (14,15), and experience a higher risk for ESKD as
noted above. Thus, for example it can be postulated that a
major component of the increased susceptibility to ESKD
among Hispanic Americans as compared with European
Americans may be attributed to the African ancestral genetic
component per se among Hispanic Americans, and that con-
versely the reduced risk in Hispanic Americans compared
with African Americans can be attributed to a lower level of
African genetic ancestry component in the former compared
with the latter. Consequently, we have studied the association
between MYH9 polymorphisms and ESKD in a study cohort
of 531 Hispanic and 894 African Americans ESKD cases
and controls. First, we characterized the global differences
in the proportions of African ancestry between the two popu-
lation samples using a set of 40 ancestry informative markers
(AIMs) and highlighted the local differences in the proportions
of African ancestry using 38 additional SNPs on chromosome
22. Second, following correction for global and local ances-
tries we found that Hispanic Americans share a higher fre-
quency compared with Europeans of three of the four most
closely spaced E-1 risk haplotype SNPs located together on
intron 23 (rs4821480, rs2032487, rs4821481) previously
described among African Americans. Third, to allow a ﬁner
mapping for association within the MYH9 gene, we have
extended the genotyping to include 42 SNPs and studied
them in the combined dataset of African and Hispanic
Americans, yielding novel polymorphisms aggregating in
two haplotypes, termed S-1 and F-1. The S-1 polymorphisms
show an even stronger association with ESKD susceptibility
compared with previously reported polymorphisms in both
recessive and additive inheritance modes, although association
for the F-1 polymorphisms is evident in the current study in
dominant and additive inheritance modes (4–6). We conclude
that the common susceptibility to ESKD described among
African and Hispanic Americans relates to their shared
partial African ancestry.
RESULTS
Clinical characteristics
Following the inclusion and exclusion criteria outlined in
‘Materials and Methods’, a total of 1425 affected and control
samples were available for analysis. Clinical characteristics of
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are presented in Table 1. The average age of ESKD patients
was signiﬁcantly lower (61.7+13.5) when compared with
the controls (77.3+10.8; P-value ,10
215, both Kolmo-
gorov–Smirnov test and t-test). The average age among
ESKD patients from the African American group (62.1+
13.6) was not signiﬁcantly different than that of the Hispanic
American group (60.3+13.0; Table 1). There was also no sig-
niﬁcant difference observed between the two groups in time
from initiation of renal replacement therapy, although the
gender distribution varied slightly between the African Ameri-
can group (47% female) and the Hispanic American group
(38% female, P-value 0.023 for a x
2 test of the difference
between the two populations). Of the 977 ESKD cases, the
recorded etiology was diabetic nephropathy in 541 (55.4%).
The 436 non-diabetic ESKD cases, comprised 366 (83.9%)
hypertension associated ESKD, 60 (13.8%) HIVAN and 10
(2.3%) idiopathic FSGS cases. In 7.1% of the hypertension
associated ESKD, a diagnosis of hypertensive nephrosclerosis
was available based on kidney biopsy and 21.7% of the
HIVAN cases were also diabetic. Among the 448 controls,
168 (37.5%) were diabetic, 363 (81%) were hypertensive and
149 (33.3%) were both diabetic and hypertensive. In 60 of the
977 ESKD cases, pathological diagnosis based on kidney
biopsy was available, and was deﬁned as non-speciﬁc nephro-
sclerosis in 40, FSGS in 10, HIVAN in 5 and as hypertensive
nephrosclerosis in the remaining 5.
Global and local ancestry estimates and association with
disease status
The reported cohort comprised 894 and 531 African and His-
panic Americans, respectively. It is important to note that no a
priori criteria to identify African or Hispanic American ances-
try were set and the sole criterion was the participant’s self
identiﬁcation as belonging to one of these two groups.
Density graphs of African ancestry in African and Hispanic
Americans (cases versus controls) are presented in Figure 1,
and show sharp differences between the two population
groups. Among self-identiﬁed African Americans the global
African, European and Native American genetic ancestries
(mean+SD) were 83.4+16.3, 12.2+14.5 and 4.3+6.5%
respectively, although in Hispanic Americans as deﬁned and
collected in the current study, the proportions were 31.2+
24.3, 54.3+23.5 and 14.4+16.1%, respectively. The
African American group has a signiﬁcantly larger African
component compared with the Hispanic American group
(P-value ,10
215 for both Kolmogorov–Smirnov and t-test).
As previously reported on the basis of analysis of uniparental
genomic regions (16), we ﬁnd a very low percent of Native
American ancestry in self-identiﬁed African Americans. Inter-
estingly, the Hispanic American group also showed a rela-
tively small Native American component in our analysis,
indicating that the ancestry of the Hispanic American subjects
in the current New York City based sample set, is comprised
of mostly a European–African admixture. Therefore, it is
evident that in both populations admixture is mostly of
African and European ancestry, with a signiﬁcantly larger
European component in the Hispanic population. Importantly,
a comparable proportion of global African ancestry was found
in controls and non-diabetic ESKD cases for both the African
American and Hispanic American cohorts, and global African
ancestry estimates showed little association with ESKD status
in either the Hispanic or African American populations (both
P-values .0.2, Kolmogorov–Smirnov test). No signiﬁcant
difference was observed in the percent of Native American
ancestry in non-diabetic Hispanic American cases and controls
(15.4+18 and 13.9+14.4%, respectively).
Local ancestry estimates were calculated using the ANCES-
TRYMAP program, using a total of 38 widely spread chromo-
some 22 SNPs. It should be noted that ANCESTRYMAP does
not estimate a Native American component, as it is limited to
inference on two ancestral populations. The inferred number
of African chromosomes in MYH9 was 0.87+0.72 for Hispa-
nic cases compared with 0.54+0.59 for controls, and 1.76+
0.42 for African cases compared with 1.65+0.53 in controls.
In contrast to the global ancestry estimates noted above,
these local ancestry estimates at the MYH9 locus, did show
a signiﬁcant association with non-diabetic ESKD status in
the Hispanic American population (P ¼ 0.0002 for Welch’s
two-sample t-test, P ¼ 0.0009 for Kolmogorov–Smirnov test)
and marginally signiﬁcant association in the African American
population (P ¼ 0.02 for Welch’s two-sample t-test, P ¼ 0.06
for Kolmogorov–Smirnov test).
Conﬁrmation of the ESKD E-1 allele risk in Hispanic
Americans
To examine the E-1 haplotype association with ESKD in His-
panic Americans we have restricted our analysis to the 14 pre-
viously reported MYH9 SNPs (5,6). We considered these 14
SNPs in a recessive risk inheritance model, corrected for
local and global ancestry, and applied a false discovery rate
(FDR) multiple comparison correction to their P-values (17).
Table 1. Descriptive parameters of samples included in the analysis
African Americans Hispanic Americans
Controls Non-diabetic
ESKD cases
Diabetic
ESKD Cases
Controls Non-diabetic
ESKD cases
Diabetic
ESKD Cases
Sample size 140 346 408 308 89 134
Age (average+SD) 79.6+9.5 58.7+14.6 64.9+12.1 76.3+11.2 54.9+13.0 63.8+11.7
Gender, Females (%) 62 41 52 53 38 38
BMI (average+SD) 27.2+6.1 26.1+6.3 28.5+6.7 26.7+5.6 25.6+5.5 26.6+6.1
Hypertension (HTN) (%) 81 100 99 81 98 97
Age at dialysis onset (average+SD) – 52.2+15.1 59.5+12.2 – 48.1+13.8 58.1+11.9
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limited to these 14 SNPs and our set of Hispanic patients
and controls. We conclude that three of the four E-1 poly-
morphisms are signiﬁcantly associated with non-diabetic
ESKD among Hispanic Americans. No signiﬁcant association
of these SNPs with diabetic ESKD was found in either Hispa-
nic or African Americans (Supplementary Material,
Table S4.6), as also noted in previous studies for African
Americans (4,5).
Comparing our results to previous analyses in African
Americans (4–6), we note that the odds ratios (ORs) we esti-
mate for Hispanic Americans (effect size of the individual
SNPs) for non-diabetic ESKD are about 1.5-fold those
observed in African American. For example, for the three
ﬁrst E-1 SNPs (rs4821480, rs2032487, rs4821481), Freedman
et al. (6), estimated a consistent OR of about 2.4, although our
estimates are between 3.56 and 3.69. In contrast, our estimated
OR in African Americans for the same SNPs are lower than
those reported in Freedman et al. (6). However, these differ-
ences are not statistically signiﬁcant, likely due to the
smaller sample size and lower number of non-diabetic
ESKD patients in our sample set. Nevertheless, this analysis
successfully and importantly replicates a positive association
of these previously reported MYH9 polymorphisms with non-
diabetic ESKD under a recessive risk inheritance model in a
new population sample, with a different African–European
ancestry admixture proportion.
A comprehensive association map within the MYH9 gene
Our primary analysis compared all non-diabetic ESKD cases to
all controls. Therefore, with the aim of searching for stronger
associations with the non-diabetic ESKD phenotype and
attempting to narrow regions containing a potential causative
polymorphism, we extended the genotyping to a total of 42
SNPs within the MYH9 gene, for the entire sample set of
African Americans and Hispanic Americans. Supplementary
Material, Table S4.1 summarizes the list of newly genotyped
and previously reported SNPs, their physical positions (where
exon 1 was designated as the ﬁrst non-coding exon in the
50-UTR of MYH9). Supplementary Material, Tables S4.2 and
S4.3 present the genotype and the allele frequencies of each
SNP in the different groups, and Supplementary Material,
Table S4.4 presents the x
2 test for deviation from Hardy–
Weinberg proportions of each SNP for each of the population
categories. Of the various population categories, based on the
demographic history and number of generations of admixture,
the African American controls are expected to be in Hardy–
Figure 1. Ancestry distribution Graphs. Density of ancestry proportions among African and Hispanic Americans as discerned from a panel of 40 AIMs for esti-
mating global ancestry (left column) and 38 chromosome 22 SNPs for estimating local ancestry (right column), separately in the African American cohort (top
row) and the Hispanic American cohort (bottom row). In the left graphs the ancestry is shown as a percentage (on the x-axis), although in the right graphs the
local MYH9 ancestry is shown as the estimated number of chromosomes (0–2) on the x-axis. The average ancestry reported in the text is the mean of the dis-
tribution described by the corresponding curve. For example, the signiﬁcant difference in average local African ancestry in the Hispanic American cohort men-
tioned in the text (0.87 for non-diabetic ESKD cases, 0.54 for controls) is the difference between the red and black checkmarks on the x-axis in the bottom right
plot. ‘Af’ designates African ancestry, ‘Eu’ designates European ancestry and ‘NA’ designates Native American ancestry. Red lines represent non-diabetic
ESKD cases, and black lines represent controls.
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(5). Indeed, taking into account multiple test correction, no sig-
niﬁcant deviation was observed for the African American
control group. Omission of the three SNPs in Supplementary
Material, Table S4.4 (rs739101, rs1009150, rs1557536) with
borderline individual signiﬁcance for deviation from Hardy–
Weinberg equilibrium without correction for multiple
testing, would not affect the associations observed (data not
shown). Supplementary Material, Table S4.5 presents the
ORs, conﬁdence intervals and allele association P-values
after adjustment for global and local ancestry for each
inheritance mode (recessive, additive and dominant) for the
non-diabetic Hispanic American and non-diabetic African
American groups and for diabetic Hispanic American, and
diabetic African American groups (Supplementary Material,
Table S4.6). For each SNP-risk model combination, we also
combined the two scores for the African and Hispanic popu-
lations using Fisher’s x
2 approximation (18), and show this
as a combined P-value estimate for the SNP. We then per-
formed a FDR correction for positively correlated tests (17),
considering the total number of tests of MYH9 SNPs (42  
3 ¼ 126). We note that the FDR correction represents a conser-
vative choice due to the positive correlation between the tests.
We prefer this conservative approach because it always guaran-
tees a false discovery that is maintained at a level that is no
higher than the desired 0.05 level. The SNP-mode combi-
nations for which association testing remained signiﬁcant fol-
lowing this correction are shown in bold in Supplementary
Material, Table S4.5. Using this approach, a total of ﬁfteen
SNPs yielded signiﬁcant associations.
We concentrate our discussion on the 10 most signiﬁcantly
associated SNPs (Table 3), of which ﬁve have been previously
reported (4–6) as having signiﬁcant association with ESKD in
African Americans (rs4821480, rs2032487, rs4821481,
rs16996674, rs16996677), and ﬁve are newly reported herein
(rs11912763, rs5750248, rs2413396, rs5750250, rs2239784).
Table 3 summarizes the association results based on the
primary analysis for these 10 SNPs, which yielded any
P-values of ,0.05 with any combination of risk inheritance
model (recessive, dominant or additive) in the non-diabetic
groups (African Americans, Hispanic Americans). A second-
ary analysis comparing ESKD diabetic patients to controls
yielded no signiﬁcant correlations: no P-value for any of the
42 SNPs was ,0.01 before multiple comparisons correction
and none of these could be considered signiﬁcant under
FDR or any other reasonable multiple comparison correction
(Supplementary Material, Table S4.6).
Interestingly, these 10 SNPs can be divided into three
clusters and one additional SNP (Fig. 2 and Table 3). As
previously reported for the E-1 haplotype (5), each of the
clusters in the current study is comprised of a set of SNPs
that are in very high LD and in which each SNP within a
cluster carries the identical information as the others regarding
disease risk, and therefore are designated as haplotypes.
This grouping facilitates inferences narrowing regions of
association. The ﬁrst set contains three of the four previously
reported E-1 haplotype SNPs located in intron 23 (rs4821480,
rs2032487, rs4821481), all of which are in very high LD
(Supplementary Material, Fig. S1). In the current analysis,
rs3752462 (intron 13) does not have the same level of LD
or carry the same association as the three E-1 SNPs noted
above, and therefore the designation ‘E-1 haplotype’ in the
current study refers to rs4821480, rs2032487, rs4821481. A
second cluster comprised three SNPs, rs5750248, rs2413396,
rs5750250, also in very high LD (r
2 ¼ 0.77, D0 ¼ 0.93 for
the latter two in Yoruba phased haplotypes from HapMap),
and are designated herein as the S-1 haplotype. This haplotype
is also in relatively high LD with the ﬁrst set (r
2 ¼ 0.58, D0 ¼
0.89 between rs2413396 and rs4821481 in HapMap (Yoruba),
and see Supplementary Material, Fig. S1). These two haplo-
types show a similar pattern of association with non-diabetic
ESKD, in both recessive and additive modes of inheritance.
The third set, which we term the F-1 haplotype, comprises
three additional SNPs: rs16996674, rs16996677, rs11912763.
The ﬁrst two of these are in close physical proximity to each
other and within intron 3 (631 bp apart) and are located
more 50 within the gene compared with any of the SNPs pre-
viously reported to be in association with the disease pheno-
type (Fig. 2). In contrast, SNP rs11912763 at nucleotide
position 35 014 668, located in intron 33, is the most 30 associ-
ated SNP found so far. Of note, rs11912763 has an allele dis-
tribution similar to that of rs16996674, and these two SNPs are
also in high LD in the HapMap Yoruba samples (r
2 ¼ 0.54,
D0 ¼ 0.81). This risk haplotype is considerably less frequent
compared with the E-1 and S-1 haplotypes. The P-values for
risk association for the F-1 SNPs are signiﬁcant for both addi-
tive and dominant inheritance modes, and therefore not con-
sistent with the recessive inheritance mode, for which the
other disease risk SNPs are signiﬁcantly associated. Moreover,
the strength of the association and the OR related to this set,
suggests a higher degree of LD with the causative mutation.
In addition to these three haplotypes, one additional SNP
within intron 10, rs2239784, has a statistically signiﬁcant
association with non-diabetic ESKD status. It is located at
nucleotide position 35 044 581, on the 50 side of the E-1 and
S-1 SNPs, but still 30 to the rs16996674 and rs16996677 F-1
associated SNPs. It is not in high LD with any of the other
Table 2. Association of MYH9 SNPs with non-diabetic ESKD in Hispanic
Americans
SNP Mode Odds (95% CI) P FDR corrected
rs7078 Rec. 1.58 (0.99–2.53) 0.11 0.1680
rs12107
a Rec. Undeﬁned
rs735853
b Rec. ,1
rs5756129 Rec. 1.53 (1.00–2.35) 0.10 0.1680
rs5756130 Rec. 1.91 (1.02–3.56) 0.09 0.1680
rs4821480 Rec. 3.70 (1.67–8.20) 0.01 0.0417
rs2032487 Rec. 3.55 (1.60–7.89) 0.01 0.0417
rs4821481 Rec. 3.66 (1.65–8.11) 0.01 0.0417
rs3752462 Rec. 1.11 (0.67–1.84) 0.74 0.9439
rs5756152 Rec. 2.23 (0.69–7.25) 0.26 0.3677
rs1557539
a Rec. Undeﬁned
rs1005570 Rec. 2.76 (1.26–6.05) 0.03 0.1161
rs16996674 Rec. 9.56 (1.50–60.91) 0.04 0.1258
rs16996677 Rec. 4.29 (1.02–18.07) 0.10 0.1680
aSNPs rs12107, rs1557539 did not appear in their risk state from Freedman
et al. (6) in our Hispanic non-diabetic ESKD cases and were therefore
inestimable in terms of risk.
bSNP rs735853 gave a slight negative estimate in the logistic regression model,
implying no added risk and its results are therefore not shown.
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2 , 0.3, D0 , 0.65 with the ﬁve other SNPs in
HapMap reported Yoruba phased haplotypes). It should be
noted that the set of SNPs previously designated as L-1 in
Freedman et al. (6) (rs7078, rs12107, rs735853 and
rs5756129) are in LD with the E-1, S-1 and F-1 SNPs, but
were not found to be signiﬁcantly associated with the
disease phenotype in the current study. We interpret this as
indicating a weaker association of the SNPs comprising the
L-1 haplotype, which therefore do not show up as signiﬁcant
in our smaller sample sets.
Although the frequency of the African ancestry risk variants
is lower among Hispanic Americans compared with African
Americans, it is of interest (Table 3 and Supplementary
Material, Table S4.5), that there is a higher OR for the risk
genotypes in the Hispanic compared with African American
cohorts. For example, the estimated odds attributable to
having one copy of SNP rs11912763 is 1.67 (67% higher
risk) in African Americans, compared with 4.59 in Hispanic
Americans. These differences persist across multiple associ-
ated SNPs, as evidenced by non-overlapping conﬁdence inter-
vals and signiﬁcant P-values between Hispanic and African
Americans for all three F-1 SNPs in Table 3. A formal t-test
gives non-corrected two-sided P-values of between 0.011
and 0.025 for the six tests for F-1 SNPs in additive and domi-
nant modes, which lose signiﬁcance when a conservative mul-
tiple comparisons correction is applied.
Identiﬁcation of additional sets of risk SNPs
To more clearly understand the nature of association of ident-
iﬁed risk SNPs and the disease phenotype we performed two
additional analyses. First, for each highly associated SNP, we
examined whether it is sufﬁcient to fully explain the correlation
betweenglobalandlocalAfricanancestryandtheprevalenceof
ESKD (4). Second, for each highly associated SNP, we exam-
inedwhichadditionalhighlyassociatedSNPscontain‘indepen-
dent’ information about ESKD status, as expressed by their
statistically signiﬁcant additive effect when included in the
logistic regression. Each one of the highly associated SNPs in
our analysis rendered both local and global ancestry insigniﬁ-
cant in determining ESKD status, when considered together
in a logistic regression model. Thus, we can conclude that at
least within our limited dataset we are capturing the major
share of the information about ESKD susceptibility in the
MYH9 gene by including any of the highly correlated SNPs
in the model. This is consistent with the ﬁndings of Kao et al.
(4), who found that each of the three E-1 SNPs was sufﬁcient
to explain fully the effect of local ancestry on ESKD risk.
To examine the excess information in pairs of SNPs, we
chose one representative SNP from each of the sets E-1
(rs4821481), S-1 (rs5750250), F-1 (rs11912763), and for each
such pair, modeled association using both SNPs according to
the risk inheritance mode which yielded the most signiﬁcant
Table 3. Association of extended MYH9 SNP clusters with non-diabetic ESKD in African and Hispanic Americans
SNP Designation African Americans Hispanic Americans Meta analysis, P FDR corrected
Mode Odds (95% CI) P Mode Odds (95% CI) P
rs11912763 F-1 Rec. 1.96 (0.97,3.99) 1.180E201 Rec. 4.84 (1.16,20.25) 6.99E202 4.78E202 1.37E201
Add. 1.55 (1.17,2.06) 1.163E202 Add. 3.71 (2.13,6.44) 9.61E205 1.64E205 4.37E204
Dom. 1.67 (1.17,2.39) 1.721E202 Dom. 4.59 (2.44,8.61) 6.88E205 1.73E205 4.37E204
rs4821480 E-1 Rec. 2.00 (1.37,2.92) 2.576E203 Rec. 3.70 (1.67,8.20) 6.88E203 2.11E204 2.96E203
Add. 1.63 (1.23,2.16) 4.658E203 Add. 1.80 (1.13,2.86) 3.85E202 1.72E203 1.14E202
Dom. 1.43 (0.82,2.51) 2.867E201 Dom. 1.21 (0.69,2.12) 5.69E201 4.59E201 6.15E201
rs2032487 E-1 Rec. 1.90 (1.30,2.76) 4.947E203 Rec. 3.55 (1.60,7.89) 8.94E203 4.88E204 4.73E203
Add. 1.57 (1.19,2.09) 8.453E203 Add. 1.75 (1.10,2.78) 4.88E202 3.63E203 1.99E202
Dom. 1.39 (0.79,2.44) 3.380E201 Dom. 1.19 (0.68,2.08) 6.09E201 5.31E201 6.83E201
rs4821481 E-1 Rec. 1.91 (1.31,2.79) 4.475E203 Rec. 3.66 (1.65,8.11) 7.42E203 3.76E204 3.94E203
Add. 1.60 (1.21,2.12) 5.547E203 Add. 1.74 (1.09,2.77) 5.23E202 2.65E203 1.52E202
Dom. 1.51 (0.87,2.60) 2.177E201 Dom. 1.15 (0.66,2.02) 6.77E201 4.30E201 5.88E201
rs5750248 S-1 Rec. 2.35 (1.60,3.45) 2.421E204 Rec. 4.21 (1.83,9.66) 4.41E203 1.57E205 4.37E204
Add. 1.72 (1.33,2.24) 6.387E204 Add. 1.61 (1.03,2.53) 8.01E202 5.57E204 5.01E203
Dom. 1.55 (0.96,2.50) 1.353E201 Dom. 1.06 (0.62,1.83) 8.55E201 3.65E201 5.25E201
rs2413396 S-1 Rec. 2.18 (1.50,3.18) 6.658E204 Rec. 3.19 (1.40,7.29) 2.07E202 1.68E204 2.64E203
Add. 1.59 (1.23,2.06) 2.697E203 Add. 1.60 (1.03,2.47) 7.78E202 1.99E203 1.24E202
Dom. 1.38 (0.86,2.21) 2.668E201 Dom. 1.22 (0.73,2.05) 5.27E201 4.16E201 5.76E201
rs5750250 S-1 Rec. 2.53 (1.72,3.72) 7.890E205 Rec. 3.87 (1.67,8.97) 8.12E203 9.77E206 4.37E204
Add. 1.79 (1.38,2.33) 2.266E204 Add. 1.50 (0.96,2.35) 1.39E201 3.58E204 3.94E203
Dom. 1.59 (1.00,2.54) 1.031E201 Dom. 1.00 (0.58,1.73) 9.88E201 3.35E201 5.14E201
rs2239784 – Rec. 1.95 (1.34,2.82) 3.217E203 Rec. 2.49 (1.26,4.93) 2.80E202 9.28E204 6.88E203
Add. 1.70 (1.32,2.20) 5.829E204 Add. 1.46 (1.00,2.13) 1.00E201 6.27E204 5.27E203
Dom. 2.04 (1.29,3.23) 1.028E202 Dom. 1.20 (0.72,2.01) 5.50E201 3.49E202 1.07E201
rs16996674 F-1 Rec. 2.02 (0.99,4.09) 1.030E201 Rec. 9.56 (1.50,60.91) 4.49E202 2.95E202 9.78E202
Add. 1.53 (1.15,2.03) 1.416E202 Add. 4.01 (2.29,7.03) 4.52E205 9.76E206 4.37E204
Dom. 1.62 (1.13,2.30) 2.570E202 Dom. 4.31 (2.33,7.97) 8.95E205 3.22E205 6.76E204
rs16996677 F-1 Rec. 1.82 (0.99,3.35) 1.043E201 Rec. 4.29 (1.02,18.07) 9.62E202 5.62E202 1.49E201
Add. 1.39 (1.06,1.82) 4.319E202 Add. 3.30 (1.95,5.58) 1.86E204 1.02E204 1.84E203
Dom. 1.43 (1.00,2.02) 9.641E202 Dom. 3.73 (2.08,6.71) 2.18E204 2.48E204 3.12E203
Boldface indicates statistically signiﬁcant P values according to the criteria described in the text.
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expected, the E-1/S-1 SNPs mostly compensate for each
others’ effects, and so are less signiﬁcant in such a model
when considered together. In a meta-analysis combining both
African American and Hispanic American results of the
model comprising both E-1 and S-1, the P-value for E-1 was
0.53 and for S-1 0.022. Thus, S-1 may contain a little infor-
mation beyond E-1, but this conclusion is very fragile in the
face of possible multiple comparison corrections. On the
other hand, when combining one SNP from E-1 or S-1 with
the F-1 SNP, both are clearly signiﬁcant in the resulting
model, indicating that the E-1/S-1 group and the F-1 group
carry distinctly different information about the risk for non-
diabetic ESKD. In a similar meta-analysis of the model com-
prising both S-1 and F-1, the corresponding P-values were
0.00081 and 0.00095, respectively.
DISCUSSION
ESKD is a major and growing health concern worldwide,
especially in the developing regions of the world, resulting
in reduced duration and quality of life, and necessitating
ongoing renal replacement therapy to sustain life. Population
discrepancies in the incidence and prevalence rates of ESKD
within the USA and other constituencies have motivated the
successfulsearchforandtherecentidentiﬁcationofgeneticsus-
ceptibilityfactors,whichprovideimportantinsightsindevelop-
ing disease preventive measures. Speciﬁcally, African ancestry
sequencevariantsintheMYH9genehavebeenshowntoconfer
major disease risk susceptibility for a number of non-diabetic
etiologies of ESKD (4–6). More recently, association
between MYH9 and albuminuria was detected in hypertensive
African Americans (13), and association between other poly-
morphisms in the same gene with serum creatinine concen-
trations has been reported in Europeans (12). Additionally,
numerous rare exonic variants have already been reported to
cause ESKD in the context of a set of syndromes (Giant Platelet
Syndromes) with autosomal dominant inheritance (19). These
observations suggest a fundamental role of variants in the
MYH9 gene in the pathogenesis of non-diabetic ESKD. The
association of a set of common polymorphic variants, whose
frequency differs among ancestral populations with more
common forms of non-diabetic ESKD, points to the existence
Figure 2. MYH9 LD plot and ESKD associated SNPs. (A) Color scheme (D0/LOD) of the 42 MYH9 SNPs that were genotyped in this study based on the African
American control samples (n ¼ 140) was generated using the program HaploView (35). Bright red squares present SNPs with linkage LOD   2 and D0 ¼ 1. The
plot overlaps the actual locations of the SNPs tested herein and the physical map of the MYH9 gene. The SNPs demonstrating the highest peaks for association
and their clustering into the haplotypes S-1 (rs5750248, rs2413396, rs5750250), E-1 (rs4821480, rs2032487, rs4821481) and F-1 (rs11912763, rs16996674,
rs16996677) and the solo tenth SNP (rs2239784) are marked. A block of reduced recombination, bordered at its 50 end with a 53 bp variable number
tandem repeat in intron 11, determined using the program PHASE 2.1 (36), corresponds to the black triangle outline in the LD plot. (B) Pie charts of genotypes
frequencies in non-diabetic ESKD cases versus controls for two SNPs representing the novel haplotypes S-1 (rs5750250) and F-1 (rs11912763) are shown for
African and Hispanic Americans. The signiﬁcant OR value for each SNP of the speciﬁed tested model is also indicated.
1822 Human Molecular Genetics, 2010, Vol. 19, No. 9of one or more causative variants with which these associated
SNPs are in LD. This raises the question of whether multiple
common causative disease susceptibility variants within the
same gene are responsible for the same ESKD phenotype, and
whether they interact with each other. Conversely, it is impor-
tant to establish whether the same causative variant confers
risk due to shared ancestry among different populations.
The Hispanic American population demonstrates an inter-
mediary pattern of ESKD susceptibility when compared with
African and Europeans Americans (1), but the pathogenetic
basis for this observation remains unknown. The previously
reported partial African ancestry among Hispanic Americans
has led us to hypothesize that the same ESKD risk polymorph-
isms reported among African Americans might also explain the
elevated susceptibility to kidney disease observed among His-
panic Americans. Our results show that 30% of the global
genetic ancestry observed among the Hispanic Americans in
thisstudycanbeattributedtoanAfricancomponentconﬁrming
theirpartiallysharedancestrywithAfricanAmericans.Interest-
ingly, local African ancestry measures for chromosome 22,
where the MYH9 gene is located, were highly associated with
ESKD in Hispanic Americans, whereas only marginally associ-
ated in African Americans. This observation suggests that
analysis of the Hispanic American population according to
local chromosome 22 ancestry estimators might better identify
the subpopulations included under the self-identiﬁed desig-
nation of Hispanic American, at higher risk for ESKD. A
further proof of the important role that the African ancestry
component contributes to the higher susceptibility to ESKD
observed among Hispanic Americans, is evident from the posi-
tive conﬁrmation of the association between the reported E-1
risk haplotype and non-diabetic ESKD among Hispanic
Americansaftercorrectionsforbothglobalandlocalancestries.
Cumulatively, our results show that, similarly to the case of
African Americans, the higher proportions of non-diabetic
ESKD observed among Hispanic Americans in the current
study are MYH9-associated. Therefore, the overall higher inci-
dencerateofESKDobservedamongHispanicAmericanswhen
compared with European Americans is likely to be attributable
at least in part, to the same African population common causa-
tivevariantwithwhichtheE-1riskpolymorphismsareinstrong
LD. Likewise, the overall lower incidence of ESKD cases
observed among Hispanic Americans when compared with
African Americans is explained by the overall lower African
ancestry component, and hence lower frequencies of the
African MYH9 risk alleles among Hispanic Americans. More-
over, our ﬁndings and analyses are entirely consistent with the
existence of an African ancestry causative variant with which
the highly associated SNPs are in LD, and which is responsible
for the excess disease phenotype risk. This inference is greatly
strengthened by the ﬁnding that the very same African ancestry
SNPsarethemosthighlyassociatedwiththecorrespondingrel-
evant ESKD phenotypes in two different populations with
varying genomic backgrounds and degrees of African ancestry
admixture. It is likely that this African ancestry causative
variant shared between the populations studied, is necessary
but not sufﬁcient for pathogenesis of the relevant ESKD pheno-
types of interest and that epistatic interactions with other
genomic regions and/or gene-by-environment interactions are
additionally necessary for penetrance of the disease phenotype.
In this regard, the observation of higher ORs for risk geno-
types in Hispanic Americans compared with African
Americans warrants consideration. Since these associations
are obtained using logistic regression—this is not an expected
effect of lower levels of African ancestry and lower disease
prevalence among the Hispanic Americans. One possible
explanation that motivates further study is that the African
genomic background may contain as yet unidentiﬁed or
untested ESKD risk variants at other loci but with lesser
effect, and which are less frequent in the European genomic
background. Thus, in the Hispanic American ESKD cases
the lower frequency of observed African-risk variants of
MYH9 may be acting on a mostly ‘protective’ European
genomic background, in contrast to African Americans
where the African-risk variants of MYH9 are acting on the
background of a higher genomic risk for ESKD. Therefore,
the relative effect of risk MYH9 variant in Hispanic Americans
would be more prominent than in African Americans. Differ-
ences in ESKD risk allele frequencies at multiple loci within
a population could arise through a variety of mechanisms,
including selective effects. This would motivate the search for
additional proposed ESKD risk loci (20–25).
The conﬁrmation of the association between the previously
reported E-1 haplotype and non-diabetic ESKD among Hispa-
nic Americans lends further support to the role of the MYH9
in the phenotype of non-diabetic ESKD, but does not facilitate
progress towards identifying a risk causing mutation.
Additional genotyping within the MYH9 gene to a total of
42 SNPs within the MYH9 gene, does however both
strengthen the association of the gene with the disease pheno-
type, and also provides potential insights pertaining to the
region containing the causative mutation and its mode of
inheritance. In this regard, our results yielded a total of 15 sig-
niﬁcantly associated SNPs, of which the 10 most signiﬁcant
clustered into three sets (Fig. 2). These results clearly show
that the S-1 SNPs (rs5750250, rs2413396, rs5750248) and
F-1 SNPs (rs16996674, rs16996677, rs11912763), have a
stronger association with non-diabetic ESKD when compared
with the SNPs reported to comprise the E-1 haplotype. Of
interest, these SNPs are found on both the 50 and 30 sides of
the E-1 haplotype SNPs, spanning a region of 42 kb. The
S-1 SNPs which are the most highly associated, are clustered
in a smaller region of only 5.5 kb between intron 13 to intron
15 and like the E-1 SNPs have the strongest association in the
recessive inheritance mode. The F-1 SNPs show a signiﬁcant
association with disease risk under a dominant or additive
inheritance mode, even though they are located furthest 50
and 30 in relation to the SNPs comprising the E-1 and S-1
risk haplotypes, which demonstrate a signiﬁcant disease risk
association in the recessive or additive inheritance mode.
This ﬁnding may suggest that even one copy of the causative
mutation may already confer some of the increased risk for
this disease phenotype. Stronger association of the E-1 and
S-1 SNPs in the recessive mode may reﬂect the fact that in
the presence of two risk alleles, the likelihood of recombina-
tion between the causative mutation variant and the E-1 or
S-1 risk variant occurring on both parental chromosomes is
greatly reduced. Thus, it will be difﬁcult to draw inferences
about the physical location of the causative variant based
only on the strength of association in a recessive inheritance
Human Molecular Genetics, 2010, Vol. 19, No. 9 1823mode, without a more complete phylogenetic resolution or
functional studies of candidate causative mutations at the mol-
ecular and mechanistic levels.
Some potential limitations of the study relate primarily to
classiﬁcation of subjects in the various disease status cat-
egories. Thus, it is as yet unclear whether the MYH9 associ-
ations relate primarily to FSGS, in which case inclusion of
hypertensive ESKD without a biopsy diagnosis of FSGS,
would weaken any inferences of association with FSGS per
se. Conversely, inclusion of subjects with undiagnosed
FSGS among those with a medical record diagnosis of diabetic
nephropathy, or inclusion of early chronic kidney disease
patients among the controls would certainly not mitigate,
and also only weaken any inferences of positive associations.
Clearly, the greater accuracy regarding the state and under-
lying etiology of chronic kidney disease would only render
the estimates of strengths of association more secure and accu-
rate. Unfortunately, clinical practice, in which kidney biopsy
is often not indicated or carried out prior to initiation of
renal replacement therapy, leaves the etiology as presumed,
solely on the basis of clinical background.
The potential clinical relevance of the results, presented pre-
viously and herein, with respect to clinical and public health
warrants some consideration. Thus questions regarding optim-
ization in kidney transplant donation can be considered, and
thresholds for instituting antiretroviral therapy in HIV-infected
individuals might be inﬂuenced by consideration of MYH9
genotypic risk for HIVAN. The current considerations for a
physician counseling a patient with normal kidney function
and a genetic risk proﬁle for chronic kidney disease at the
MYH9 gene are complex, since the actual disease-risk causa-
tive variant is as yet unknown, and as only a minority of indi-
viduals bearing the MYH9 risk haplotypes will eventually
develop ESKD likely reﬂecting the contribution of epistatic
genomic as well as environmental factors (26,27). Of note,
the current results comparing MYH9 risk allele effects in
African and Hispanic Americans highlight the contribution
of differing population genomic backgrounds in MYH9
associated ESKD risk. Nevertheless, it seems reasonable
for a physician to include the status of the MYH9 risk haplo-
type as one of the many considerations used in ESKD risk
assessment.
In summary, our results demonstrate that the same MYH9
risk haplotypes are associated with non-diabetic ESKD in
both African and Hispanic Americans as a result of their par-
tially shared African ancestry. The ﬁnding of this association
within the Hispanic American population, in which the
overall global African ancestry is signiﬁcantly lower when
compared with African Americans, predicts a functional
impact of the MYH9 local African ancestry to ESKD suscep-
tibility, and adds very strong support for the existence and
hence motivates the search for a causative disease phenotype
risk variant. We have further identiﬁed additional SNPs in
the MYH9 gene, grouped in clusters designated as S-1 and
F-1 that show the strongest associations reported to date
with ESKD in both African and Hispanic Americans. More-
over, the ﬁnding of signiﬁcant independent associations in
both dominant and additive inheritance modes for the F-1
SNPs, and recessive and additive inheritance modes for the
S-1 SNPs, means that the search for the causative mutation
should take into account the possibility that a single copy
may confer a functional effect. Taken together, these ﬁndings
strongly motivate the search for a functional African ancestry
causative MYH9 variant, which will be facilitated by a deeper
understanding of the phylogenetic history of the locus.
MATERIALS AND METHODS
Subjects
The study included a total of 1425 individuals collected at
dialysis clinics (ESKD) and ambulatory clinics and nursing
centers (controls) afﬁliated with the Cabrini Medical Center,
New York City, USA, and approved by its Institutional Review
BoardforbothESKDpatientsandcontrols.Allstudyparticipants
provided written informed consent. It should be noted that none
ofthesamplesreportedinthecurrentstudyoverlapthosereported
in the companion study by Nelson et al. (28).
Participants self reported their ancestry to be African or His-
panic American. A total of 894 African Americans were
recruited, of whom 754 were ESKD patients and 140 were
controls. Likewise, a total of 531 Hispanic Americans were
enrolled, of whom 223 and 308 subjects were ESKD and
control subjects, respectively (Table 1). During recruitment,
the following information was collected for each of the poten-
tial participants by direct questioning and by reviewing the
participant’s medical records: height, weight, age, gender,
place of birth, parental place of birth, self-reported ethnicity,
kidney function status (ESKD or plasma creatinine concen-
tration), kidney biopsy diagnosis when available, ESKD dur-
ation, and known high blood pressure, diabetes or HIV
diagnosis preceding initiation of renal replacement therapy.
As noted from the subject and parental place of birth infor-
mation, the self-identiﬁed Hispanic American subjects in the
current study, were mostly of Puerto Rican, Dominican and
other Caribbean parental ancestry, with few subjects of
Mexican-American afﬁliation, consistent with the recruitment
location in New York City. This was also evident in the ances-
try marker panel analysis, indicating a relative paucity of
Native American ancestry markers. Thus, use of the term His-
panic American in the context of the current study refers to
Hispanic Americans mostly of Caribbean origin, who inherit
predominant European and African ancestry. This is in con-
trast to the use of the term Hispanic American in other
studies, which often include many Mexican Americans who
inherit predominant European and Native American ancestry.
Since the current study refers to European and African ances-
try, the Hispanic American sub-groups in our sample set are of
particular interest for the current analysis.
Hypertension associated kidney disease refers to patients
whohaveamedical historyofhypertension preceding initiation
of renal replacement therapy, but who do not have diabetes,
HIV infection or other known speciﬁc etiologies of kidney
disease, and in whom renal biopsy information was usually
not available. In a small subset of these cases a renal biopsy
diagnosis of ‘hypertensive nephrosclerosis’ was available. Dia-
betes (type 1 and 2) was deﬁned as self-reported and/or preva-
lent treatment with insulin and/or oral hypoglycemic agents or
diabetes mellitus documented in the medical history. The diag-
nosisofHIVAN wasmade inthe presence ofknownHIV infec-
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nosisofidiopathicFSGSwasmadeonlyinthepresenceofcom-
patible renal biopsy information. Non-diabetic ESKD cases in
our sample set correspond to the union of H-ESKD patients
as described in the companion paper (28) with FSGS, HIVAN
and ESKD patients, exclusive of the following etiologies: con-
genital, obstructive, cancer-related kidney diseases or known
monogenic forms of kidney disease (e.g. autosomal dominant
polycystic kidney disease, Alport syndrome).
Unrelated control subjects were recruited from the general
population without known kidney disease at age 55 or
greater. Medical history of hypertension or diabetes was also
recorded for each of the control individuals. Creatinine con-
centrations were available in all of the controls, and individ-
uals with creatinine concentration exceeding 1.7 were
excluded. We recognize that these controls may have included
some individuals with undiagnosed early stages of chronic
kidney disease. Inadvertent classiﬁcation of such individuals
as unaffected would not mitigate and only strengthen the infer-
ence of any possible positive association of the affected status
with genomic SNPs or haplotypes in the overall analysis.
To estimate ancestral population allele counts for global
ancestry we included a total of 284 samples available to us
from the Coriell collection and as detailed in Supplementary
Material, Table S1.
Genotyping
Genomic DNA was obtained from peripheral blood samples
using standard phenol-chloroform extraction protocols (29).
The KasPar methodology (30) was used to genotype all 119
SNPs reported herein. For global ancestry estimation we used
informationfromHapMap(31)andnovelinformationfromgen-
otyping of 40 genomic AIMs in samples from different world
populations (Supplementary Material, Tables S1 and S2). Fol-
lowing that, we genotyped the complete set of samples (n ¼
1425) in order to appropriately evaluate population ancestry
for each individual and the potential of population substructure.
For local ancestry estimation, a total of 38 additional SNPs
restricted to chromosome 22 were selected for genotyping
usingtherecentlyreportedexpectedmutualinformationancestry
measure (32) (Supplementary Material, Table S3). To achieve
ﬁne mapping within the MYH9 gene, a total of 42 SNPs were
genotyped, as shown in Supplementary Material, Table S4.1.
These consisted of 14 SNPs originally reported in Kopp et al.
(5)plusanadditional28SNPsidentiﬁedinthecompanionmanu-
script (28), as potentially informative based upon skewed
HapMap population frequencies and providing broad coverage
across the MYH9 region, especially the region spanned by the
previously identiﬁed E-1 haplotype (5). Duplicate samples
(7.3%) were distributed across plates to assess for consistency
between genotype calls. The error rate observed among the
duplicated samples was ,0.05%. No contaminating DNA
signals were observed in water-only controls. Samples with
,90% complete call rate were excluded from analysis.
Ancestry estimation
We generated both global and local African ancestry pro-
portion estimates for each of the samples in our data. To
estimate global ancestry, we utilized the 40 AIMs shown in
Supplementary Material, Table S2 and a maximum likelihood
approach assuming a multinomial distribution for the ancestry
of each marker, as described in Tang et al. (33). The popu-
lation proportion information data used for estimating ances-
tral population proportions was taken from HapMap (31)
(for European and African ancestry) and from our novel
dataset (Supplementary Material, Table S1) (European,
African and Native American ancestry). To estimate local
ancestry, we used the program ANCESTRYMAP, using a
total of 38 SNPs restricted to chromosome 22 (Supplementary
Material, Table S3) and extracted local ancestry estimates for
SNP rs2157257, which is located within the MYH9 gene
itself. Since recent admixture is expected to generate long hap-
lotype blocks (34), it is not necessary to estimate local ances-
try separately for each SNP being investigated, and a single
estimate of local ancestry at the MYH9 locus for each
sample was used.
Modeling association for MYH9 polymorphisms
As in previous studies (5,6), we used logistic regression to
estimate the increase in risk attributable to the allele variant
at each of the genetic markers tested in each of our two popu-
lations of African Americans and Hispanic Americans,
although controlling for other potential stratiﬁcation effects,
in particular local and global African ancestry and self identi-
ﬁcation as African American or Hispanic American. We did
not control for age since one of our criteria for collecting con-
trols was an older age, in particular the age of all controls was
.55 years and as a result controls were signiﬁcantly older
than the ESKD patient cohort (Table 1).
For each SNP we considered three possible modes of
genetic effect on risk:
(i) Dominant: one risk allele is sufﬁcient to incur all excess
risk.
(ii) Additive: each additional risk allele makes a measurable
contribution to excess risk. More formally, in the frame-
work of logistic regression this model assumes additivity
of the log-odds of disease, i.e. a multiplicative effect on
the OR.
(iii) Recessive: two risk alleles are required to incur any
excess risk.
What differentiates the three modes is the manner in which
the SNP is used in the logistic regression. For the dominant
mode we introduced a binary variable, equal to 1 if at least
one risk allele is present and 0 otherwise. For the additive
mode, the number of risk alleles (0, 1, 2) is used as a covariate
in the logistic regression. For the recessive mode, we again
deﬁne a binary variable, but this time it is 1 only if two risk
alleles are present and 0 otherwise.
To validate the association between MYH9 polymorphisms
and the ESKD phenotype we divided our entire dataset to three
phenotypic groups: diabetic ESKD patients, non-diabetic
ESKD patients and controls (Table 1). Included in the non-
diabetic ESKD patients were hypertension associated ESKD,
FSGS and HIVAN patients, as deﬁned above. Controls, as
deﬁned above, were either diabetic or non-diabetic, but
without ESKD at age greater than 55. One small group of
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for both HIVAN and diabetes were included in the group of
non-diabetic ESKD HIVAN patients, following conﬁrmation
that their inclusion under diabetic ESKD or exclusion from
the analysis did not change our results. In total, under the
assumption that the main risk mode of MYH9 is for non-
diabetic ESKD (4–6), our primary analysis compared all non-
diabetic ESKD cases to all controls. We recognize that some
patients with a medical record diagnosis of diabetic ESKD,
and without a conﬁrmatory biopsy, may actually have a
primary non-diabetic glomerulopathy, including some with
undiagnosed FSGS (7). Exclusion of these patients from the
‘affected’ cohort would only weaken our ability to uncover a
positive association of SNPs and haplotypes in the MYH9
gene with the ‘affected’ disease phenotype, and therefore not
mitigate inferences of a positive association.
Analysis of MYH9 SNPs
Previously published analyses of risk SNPs in MYH9 (4–6)
have identiﬁed a collection of four SNPs (rs4821480,
rs2032487, rs4821481, rs3752462) in strong LD and which
together were termed the E-1 haplotype, which was the most
highly correlated with non-diabetic ESKD occurrence, under
a recessive transmission risk model. In our study, we did not
detect a signiﬁcant association with ESKD for the SNP
rs3752462, therefore the E-1 haplotype mentioned herein
refers only to the three adjacent SNPs located in intron 23
(rs4821480, rs2032487, rs4821481). An additional 10 MYH9
SNPs (rs7078, rs12107, rs735853, rs5756129, rs5756130,
rs5756152, rs1557539, rs1005570, rs16996674, rs16996677)
were identiﬁed as having weaker associations. We chose all
14 of these SNPs for a conﬁrmatory study in our Hispanic
American sample set. On the basis of the inferred mode of her-
editary risk transmission for positive association in these pre-
vious studies, we chose to model them as following a recessive
risk model. We then extended the analysis to the full set of
MYH9 SNPs (Supplementary Material, Table S4.1) under
the inheritance models noted above.
SUPPLEMENTARY MATERIAL
Supplementary material is available at HMG online.
ACKNOWLEDGEMENTS
The authors wish to thank the participating subjects and the
physicians afﬁliated with the Cabrini Medical Center and its
afﬁliates for their participation in sample and data acquisition,
and Dr. Alan Templeton for his valuable input.
Conﬂict of Interest statement. None declared.
FUNDING
This work was supported by the Canadian and American
Technion Societies (Eshagian Estate Fund, Veronique Elek
Fund, Dr Sidney Kremer Kidney Disease Research Fund);
the Israel Science Foundation (890015), and Legacy Heritage
Fund; to K.S. The European Research Commission
(MIRG-CT-2007-208019); and the Israel Science Foundation
(1227/09); to S.R. The National Cancer Institute, National
Institutes of Health (HHSN261200800001E); the Intramural
Research Program of National Cancer Institute, Center for
Cancer Research (the content of this publication does not
necessarily reﬂect the views or policies of the Department of
Health and Human Services, nor does mention of trade
names, commercial products or organizations imply endorse-
ment by the US Government); and the National Institute for
Diabetes, Digestive and Kidney Diseases (Project ZO-1
DK043308), to J.B.K.
REFERENCES
1. USRDS (2008) Annual Data Report: Atlas of Chronic Kidney Disease and
End-Stage Renal Disease in the United States., National Institutes of
Health, National Institute of Diabetes and Digestive and Kidney Diseases,
Bethesda, MD.
2. Kopp, J.B. and Winkler, C. (2003) HIV-associated nephropathy in African
Americans. Kidney Int. Suppl., 63, S43–S49.
3. Kitiyakara, C., Kopp, J.B. and Eggers, P. (2003) Trends in the
epidemiology of focal segmental glomerulosclerosis. Semin. Nephrol., 23,
172–182.
4. Kao, W.H., Klag, M.J., Meoni, L.A., Reich, D., Berthier-Schaad, Y., Li,
M., Coresh, J., Patterson, N., Tandon, A., Powe, N.R. et al. (2008) MYH9
is associated with nondiabetic end-stage renal disease in African
Americans. Nat. Genet., 40, 1185–1192.
5. Kopp, J.B., Smith, M.W., Nelson, G.W., Johnson, R.C., Freedman, B.I.,
Bowden, D.W., Oleksyk, T., McKenzie, L.M., Kajiyama, H., Ahuja, T.S.
et al. (2008) MYH9 is a major-effect risk gene for focal segmental
glomerulosclerosis. Nat. Genet., 40, 1175–1184.
6. Freedman, B.I., Hicks, P.J., Bostrom, M.A., Cunningham, M.E., Liu, Y.,
Divers, J., Kopp, J.B., Winkler, C.A., Nelson, G.W., Langefeld, C.D. et al.
(2009) Polymorphisms in the non-muscle myosin heavy chain 9 gene
(MYH9) are strongly associated with end-stage renal disease historically
attributed to hypertension in African Americans. Kidney Int., 75, 736–
745.
7. Freedman, B.I., Hicks, P.J., Bostrom, M.A., Comeau, M.E., Divers, J.,
Bleyer, A.J., Kopp, J.B., Winkler, C.A., Nelson, G.W., Langefeld, C.D.
et al. (2009) Non-muscle myosin heavy chain 9 gene MYH9 associations
in African Americans with clinically diagnosed type 2 diabetes
mellitus-associated ESRD. Nephrol. Dial. Transplant., 24, 3366–3371.
8. Anochie, I.C., Eke, F.U. and Okpere, A.N. (2008) Human
immunodeﬁciency virus-associated nephropathy (HIVAN) in Nigerian
children. Pediatr. Nephrol., 23, 117–122.
9. Han, T.M., Naicker, S., Ramdial, P.K. and Assounga, A.G. (2006) A
cross-sectional study of HIV-seropositive patients with varying degrees of
proteinuria in South Africa. Kidney Int., 69, 2243–2250.
10. Nochy, D., Glotz, D., Dosquet, P., Pruna, A., Guettier, C., Weiss, L.,
Hinglais, N., Idatte, J.M., Mery, J.P., Kazatchkine, M. et al. (1993) Renal
disease associated with HIV infection: a multicentric study of 60 patients
from Paris hospitals. Nephrol. Dial. Transplant., 8, 11–19.
11. Behar, D.M., Shlush, L.I., Maor, C., Lorber, M. and Skorecki, K. (2006)
Absence of HIV-associated nephropathy in Ethiopians. Am. J. Kidney
Dis., 47, 88–94.
12. Pattaro, C., Aulchenko, Y.S., Isaacs, A., Vitart, V., Hayward, C., Franklin,
C.S., Polasek, O., Kolcic, I., Biloglav, Z., Campbell, S. et al. (2009)
Genome-wide linkage analysis of serum creatinine in three isolated
European populations. Kidney Int., 76, 297–306.
13. Freedman, B.I., Kopp, J.B., Winkler, C.A., Nelson, G.W., Rao, D.C.,
Eckfeldt, J.H., Leppert, M.F., Hicks, P.J., Divers, J., Langefeld, C.D. et al.
(2009) Polymorphisms in the nonmuscle myosin heavy chain 9 gene
(MYH9) are associated with albuminuria in hypertensive African
Americans: the HyperGEN study. Am. J. Nephrol., 29, 626–632.
14. Bedoya, G., Montoya, P., Garcia, J., Soto, I., Bourgeois, S., Carvajal, L.,
Labuda, D., Alvarez, V., Ospina, J., Hedrick, P.W. et al. (2006)
Admixture dynamics in Hispanics: a shift in the nuclear genetic ancestry
1826 Human Molecular Genetics, 2010, Vol. 19, No. 9of a South American population isolate. Proc. Natl. Acad. Sci. USA, 103,
7234–7239.
15. Price, A.L., Patterson, N., Yu, F., Cox, D.R., Waliszewska, A., McDonald,
G.J., Tandon, A., Schirmer, C., Neubauer, J., Bedoya, G. et al. (2007) A
genomewide admixture map for Latino populations. Am. J. Hum. Genet.,
80, 1024–1036.
16. Parra, E.J., Kittles, R.A., Argyropoulos, G., Pfaff, C.L., Hiester, K.,
Bonilla, C., Sylvester, N., Parrish-Gause, D., Garvey, W.T., Jin, L. et al.
(2001) Ancestral proportions and admixture dynamics in geographically
deﬁned African Americans living in South Carolina. Am. J. Phys.
Anthropol., 114, 18–29.
17. Benjamini, Y. and Yekutieli, D. (2001) The control of the false discovery
rate in multiple testing under dependency. Ann. Stat., 29, 1165–1188.
18. Guerra, R., Etzel, C.J., Goldstein, D.R. and Sain, S.R. (1999)
Meta-analysis by combining P-values:simulated linkage studies. Genet.
Epidemiol., 17 (Suppl. 1), S605–S609.
19. Althaus, K. and Greinacher, A. (2009) MYH9-related platelet disorders.
Semin. Thromb. Hemost., 35, 189–203.
20. Boute, N., Gribouval, O., Roselli, S., Benessy, F., Lee, H., Fuchshuber,
A., Dahan, K., Gubler, M.C., Niaudet, P. and Antignac, C. (2000) NPHS2,
encoding the glomerular protein podocin, is mutated in autosomal
recessive steroid-resistant nephrotic syndrome. Nat. Genet., 24, 349–354.
21. Gbadegesin, R., Hinkes, B.G., Hoskins, B.E., Vlangos, C.N., Heeringa,
S.F., Liu, J., Loirat, C., Ozaltin, F., Hashmi, S., Ulmer, F. et al. (2008)
Mutations in PLCE1 are a major cause of isolated diffuse mesangial
sclerosis (IDMS). Nephrol. Dial. Transplant., 23, 1291–1297.
22. Kaplan, J.M., Kim, S.H., North, K.N., Rennke, H., Correia, L.A., Tong,
H.Q., Mathis, B.J., Rodriguez-Perez, J.C., Allen, P.G., Beggs, A.H. et al.
(2000) Mutations in ACTN4, encoding alpha-actinin-4, cause familial
focal segmental glomerulosclerosis. Nat. Genet., 24, 251–256.
23. Kestila, M., Lenkkeri, U., Mannikko, M., Lamerdin, J., McCready, P.,
Putaala, H., Ruotsalainen, V., Morita, T., Nissinen, M., Herva, R. et al.
(1998) Positionally cloned gene for a novel glomerular protein–nephrin—
is mutated in congenital nephrotic syndrome. Mol. Cell, 1, 575–582.
24. Kim,J.M.,Wu,H.,Green,G.,Winkler,C.A.,Kopp,J.B.,Miner,J.H.,Unanue,
E.R. and Shaw, A.S. (2003) CD2-associated protein haploinsufﬁciency is
linked to glomerular disease susceptibility. Science, 300, 1298–1300.
25. Winn, M.P., Conlon, P.J., Lynn, K.L., Farrington, M.K., Creazzo, T.,
Hawkins, A.F., Daskalakis, N., Kwan, S.Y., Ebersviller, S., Burchette, J.L.
et al. (2005) A mutation in the TRPC6 cation channel causes familial
focal segmental glomerulosclerosis. Science, 308, 1801–1804.
26. Ward, M.M. (2008) Socioeconomic status and the incidence of ESRD.
Am. J. Kidney Dis., 51, 563–572.
27. Norris, K. and Nissenson, A.R. (2008) Race, gender, and socioeconomic
disparities in CKD in the United States. J. Am. Soc. Nephrol., 19,
1261–1270.
28. Nelson, G.W., Freedman, B.I., Bowden, D.W., Langerﬁeld, C., An, P.,
Johnson, R.C., Kopp, J.B. and Winkler, C. (2010) Fine mapping of MYH9
localizes the strongest kidney disease associations to the region of introns
13 to 15. Hum. Mol. Genet. (in press).
29. Sambrook, J., Fritsch, E. and Maniatis, T. (1989) Molecular Cloning: A
Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring
Harbor, NY.
30. Petkov, P.M., Ding, Y., Cassell, M.A., Zhang, W., Wagner, G., Sargent,
E.E., Asquith, S., Crew, V., Johnson, K.A., Robinson, P. et al. (2004) An
efﬁcient SNP system for mouse genome scanning and elucidating strain
relationships. Genome Res., 14, 1806–1811.
31. Thorisson, G.A., Smith, A.V., Krishnan, L. and Stein, L.D. (2005) The
International HapMap Project Web site. Genome Res., 15, 1592–1593.
32. Bercovici, S., Geiger, D., Shlush, L., Skorecki, K. and Templeton, A.
(2008) Panel construction for mapping in admixed populations via
expected mutual information. Genome Res., 18, 661–667.
33. Tang, H., Peng, J., Wang, P. and Risch, N.J. (2005) Estimation of
individual admixture: analytical and study design considerations. Genet.
Epidemiol., 28, 289–301.
34. Darvasi, A. and Shifman, S. (2005) The beauty of admixture. Nat. Genet.,
37, 118–119.
35. Barrett, J.C., Fry, B., Maller, J. and Daly, M.J. (2005) Haploview: analysis
and visualization of LD and haplotype maps. Bioinformatics, 21,
263–265.
36. Stephens, M., Smith, N.J. and Donnelly, P. (2001) A new statistical
method for haplotype reconstruction from population data. Am. J. Hum.
Genet., 68, 978–989.
Human Molecular Genetics, 2010, Vol. 19, No. 9 1827